Poniard Pharmaceuticals, Inc.
PARD
Rank in Stocks
#35290
Poniard Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the... Poniard Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery and market introduction of cancer treatments. Its flagship product candidate, Picoplatin, is a platinum-based therapy targeting various cancer types, such as small cell lung, colorectal, prostate, and ovarian cancers. The company has advanced Picoplatin through several clinical stages, including a pivotal Phase III SPEAR trial for small cell lung cancer patients in a second-line treatment setting. Furthermore, Phase II studies investigated Picoplatin as an initial therapy for metastatic colorectal cancer and hormone-refractory prostate cancer. An early-stage Phase I trial also examined an oral formulation of Picoplatin for solid tumors. Founded in 1984 as NeoRx Corporation, the company rebranded to Poniard Pharmaceuticals, Inc. in September 2006 and operates from its base in Seattle, Washington.
Share Price
$0.0001
Last synced: 2026-11-06
Market Cap
$150.00
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Poniard Pharmaceuticals, Inc. (PARD)
Category
Healthcare
Operating Margin for Poniard Pharmaceuticals, Inc. (PARD)
Operating Margin as of November 2026 TTM: 0.00%
According to Poniard Pharmaceuticals, Inc.'s latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2010 the company had an operating margin of 0.00%.
Operating Margin history for Poniard Pharmaceuticals, Inc. from 2000 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2010 | 0.00% | 0.00% |
| 2009 | 0.00% | 0.00% |
| 2008 | 0.00% | 0.00% |
| 2007 | 0.00% | 0.00% |
| 2006 | 0.00% | -100.00% |
| 2005 | -140,400.00% | 7,212.88% |
| 2004 | -1,919.90% | 4,213.41% |
| 2003 | -44.51% | -79.34% |
| 2002 | -215.47% | -76.32% |
| 2001 | -910.09% | 78.99% |
| 2000 | -508.45% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
|
| 29.35% | - |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Poniard Pharmaceuticals, Inc.'s operating margin
What was Poniard Pharmaceuticals, Inc.'s operating margin in 2010?
In 2010, Poniard Pharmaceuticals, Inc.'s operating margin was 0.00%, compared with 0.00% in 2009.
How has Poniard Pharmaceuticals, Inc.'s operating margin changed since 2005?
From 2005 to 2010, Poniard Pharmaceuticals, Inc.'s operating margin was highest in 2010 (0.00%) and lowest in 2005 (-140,400.00%).
How does Poniard Pharmaceuticals, Inc.'s operating margin compare with similar companies?
Poniard Pharmaceuticals, Inc.'s operating margin (0.00%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.